Novo Nordisk

Revenue for the Danish company behind the booming GLP-1 injectable drugs is up 29% so far this year.

Novo Nordisk said its blockbuster weight-loss drug Wegovy could receive expanded approval from the U.S. Food and Drug Administration within six months.

Adjusted profit came out 5.02 Danish krone per share — about 72 cents a share. Earnings grew 57% and topped expectations for 4.70 Danish krone. Sales of weight- ...

Good morning, all. Damian here with a look at the future of treating Duchenne muscular dystrophy, the departure of an influential biotech CEO, and the next ...

Novo Nordisk and Eli Lilly reported booming sales from their blockbuster diabetes and weight-loss drugs as both race to keep up with consumer demand.

The remarks come as U.S. health insurers balk at the extreme cost of Wegovy and other obesity drugs and drop them from their plans.

Today's biotech updates include the future of Duchenne treatment, the departure of BioMarin's CEO, and the next phase of the GLP-1 panic.

NVO earnings call for the period ending September 30, 2023. Logo of jester cap with thought bubble. Image source: The Motley Fool. Novo Nordisk (NVO ...

Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years - limited only by their ...

Management's updated 2023 guidance from October—32%-38% top-line growth and 40%-46% operating profit growth—is slightly above our prior expectations, as U.S. ...

Drugs helping weight-loss like Novo Nordisk's Wegovy and Eli Lilly's Mounjaro drove blockbuster sales for the pharma giants in the third quarter.

On Thursday, Novo Nordisk, the company behind Ozempic and Wegovy, reported a 29% increase in sales to $8.4 billion for the third quarter.

Bagsværd, Denmark, 3 November 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board ...